Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Misiu thanks for your believe in Dr P. I'm with you...let's all give him credit for getting this miracle so far....and let's wait patiently for the drug to get approval so every1 can be healthy (those with HIV) and rich (those who invested).
In Jamaica they say "patient man ride donkey".....(WallStreet, I know you may have heard that before)
Why is everyone bashing management for the stock price? I think they are doing a great job and we all need to be patient and enjoy the ride. The price can't be what we want it to be until the results are in and the medicine is what it claims to be.
Ok Donald Trump....Wrong!
Hey. Jamaican here too. Hope we all do well with this stock and for the sake of those with HIV, I hope this drug gets approved!
I share your sentiments. I think I'm doing something wrong too. Lol
Cure for HIV:
Recently British doctors revealed that a 44 year old man who's part of a 50 patient, experimental treatment to completely rid the body of HIV appears to have been cured.
The treatment involves giving the patient a vaccine to wake up dormant CD4 T-cells in which HIV can remain dormant, and hidden for years. Then Merck's (NYSE:MRK) Vorinostat is used to kill all the infected cells, theoretically completely clearing the body of the virus.
According to Mark Samuels, managing Director of the NIH's Health Research Office for Clinical Research Infrastructure, "This is one of the first serious attempts at a full cure for HIV."
HIV Cure Could Prove Disastrous For Gilead's Stock Price - But Don't Panic Just Yet $GILD http://www.seekingalpha.com/article/4011558
Conference Call and Webcast Instructions
CytoDyn’s management team will host a conference call and live audio webcast on Tuesday, October 11, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to further discuss the Phase 3 trial protocol modifications and the anticipated time and cost reductions, among other corporate updates.
Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).
A live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 60 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link: http://cytodyn.equisolvewebcast.com/inv-call-10-11-16.
A replay of the conference call will be available until December 11, 2016. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international); Conference ID: 13647094.
What exactly is the question do you want someone to ask?
This little birdie stuff is annoying!
I am. Not able to view my acct.
Patients Approach Two Years of Complete HIV Viral Load Suppression in Phase 2b PRO 140 Monotherapy Extension Study
GlobeNewswire
Related Investments
CytoDyn Inc
VANCOUVER, Washington, Aug. 23, 2016 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that the first of 11 HIV-1 patients receiving PRO 140 as a monotherapy in a Phase 2b extension study has reached two years of complete virologic suppression. Four additional patients are expected to reach the two-year benchmark in the next three weeks and five more patients are expected to reach this benchmark in approximately two months.
“We are pleased that 10 HIV patients who participated in our Phase 2b study are approaching the significant milestone of two years of complete virologic suppression on PRO 140 as a single agent,” said Nader Pourhassan, PhD, CytoDyn’s President and CEO. “These patients are receiving weekly subcutaneous PRO 140 injections as a substitution for daily regiments of Highly Active Antiretroviral Therapy (HAART) regimens without the notable drawbacks of HAART.”
Patients in the Phase 2b extension study showed full HIV viral load suppression during a 12-week Phase 2b study in which they receive weekly PRO 140 subcutaneous injections (one 350 mg dose) in place of their HAART regimens. Forty patients were enrolled in the Phase 2b trial, of which 35 were evaluable and five were excluded for tropism screening failures or protocol violations. Twenty patients completed the 12-week Phase 2b study with HIV viral load suppression and were eligible for the extension arm. Fifteen patients of the 20 were granted entry into the extension arm. Four of the fifteen patients that entered the extension arm were disqualified due to lack of follow-up (relocation) or disqualification unrelated to PRO 140 and one was a treatment failure, leaving 10 evaluable patients, which are now at or close to the two-year benchmark of complete HIV viral load suppression while on PRO 140 as a monotherapy.
Of the 11 patients currently receiving weekly PRO 140 injections in the Phase 2b extension study, one patient recently entered the study, having shown complete HIV viral load suppression following an initial 12-week treatment period. This patient was one of three patients who were allowed to qualify for the Phase 2b extension study within the past two to four months by the trial’s Data Safety Monitoring Board due to the disqualification of three patients in the original Phase 2b study for tropism screening errors.
Patients qualifying for the Phase 2b monotherapy study were evaluated for infection with strains of HIV-1 that utilize the CCR5 co-receptor. The PRO 140 monoclonal antibody targets CCR5 with high affinity and potently blocks HIV-1 cell entry. Complete virologic suppression is defined as plasma HIV-1 RNA less than 40 copies/mL, which is the lower limit of detection in the commercial assay. Blood drawn after one year of monotherapy from nine patients in the Phase 2b extension study were tested with a single copy HIV-1 research test. In six of the nine patients whose viral load was checked with a single copy assay, the viral load was documented to be less than one HIV-1 RNA copy/mL blood and two patients had less than 4 copies/mL.
First Patient Enrolled Under Newly Modified Protocol in CytoDyn’s Phase 3 PRO 140 Combination Study in HIV.
Revised protocol features a 50% reduction in the number of patients and relaxed enrollment criteria
http://content.equisolve.net/cytodyn/news/2016-07-26_First_Patient_Enrolled_Under_Newly_Modified_239.pdf
BRIEF-CytoDyn first patient enrolled in late-stage HIV study
*First patient enrolled under newly modified protocol in cytodyn's phase 3 pro 140 combination stud in HIV.
Reuters 07:04 AM ET July 26, 2016
I will vote yes. I trust that they know what they are doing. I think we all just need to have patience!
I agree, let's leave politics for some other board somewhere. This is about CYDY and Pro140!
I'll be direct:
Tootalljones, can you please keep your political views to yourself?
Ahhhh Chump let's all hope he isn't....
Not in the article but please read the comments.
Seeking Alpha DoctorRX's response to CYDY Pro140:
JAMA's HIV/AIDS Issue; New Treatment Recommendations: Importance To Gilead $GILD http://www.seekingalpha.com/article/3988691
March 2016 article:
https://www.poz.com/article/charlie-sheen-pining-wrong-clinical-trial-longacting-hiv-meds
"Flexner, who is also a professor of medicine at Johns Hopkins, says that a drawback of PRO 140 is its dosing frequency. While a weekly self-injectable may appeal to some people with HIV, the dominant focus in the mainstream long-acting HIV treatment research field today is on therapy that, while requiring a clinic visit for injections, is given only every eight weeks. The sole current player in this field is the long-acting injectable antiretroviral cocktail of ViiV Healthcare’s investigational integrase inhibitor cabotegravir and Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine)."
Forbes article about Sheen on Dr OZ and his disclosure that he is in the trial:
http://www.forbes.com/sites/arleneweintraub/2016/02/11/charlie-sheen-tells-dr-oz-he-wants-in-on-tiny-cytodyns-hiv-trial/#3e9c536371e3
Another article I found:
http://www.nwcn.com/entertainment/charlie-sheen-wants-to-join-hiv-clinical-trial-of-vancouver-firm/251254297
From Seeking Alpha:
tonecee
Comments (6) |+ Follow
How will Cytodyn's Pro 140 (if approved by the FDA)once a week injection for the treatment of HIV affect Gilead HIV market share?
13 Jun 2016, 11:06 AM
DoctoRx , Contributor
Comments (6895) |+ Follow |Send Message
Author’s reply »
Tonecee, I don't know. It's mostly in Phase 2. With a market cap of $0.14 B ($140 MM), I'm sure that GILD or ViiV would have bought it or partnered with it if they believed there was some reasonable commercial potential there. Dr. B did address this topic in one of his recent comments, saying that GILD is looking into a long-acting injectable, but that he didn't think there was a lot of commercial potential there.
NEW | 13 Jun 2016, 11:20 AM
Charlie Sheen reveals all about THAT meltdown, his HIV secret, family and big screen comeback:
http://www.berwick-advertiser.co.uk/what-s-on/arts-entertainment/charlie-sheen-reveals-all-about-that-meltdown-his-hiv-secret-family-and-big-screen-comeback-1-4130772